Trial Profile
Open Label, Phase I/II Trial of Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura (ITP)in Children and Adolescents
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 29 Apr 2015 New trial record